Literature DB >> 18446470

Estimating the number of droplets and drug particles emitted from MDIs.

Stephen W Stein1.   

Abstract

The objective of this paper is to assess the number of drug particles or droplets contained in metered dose inhaler (MDI) aerosols. Equations were developed to estimate this. The number of drug particles was estimated to be as high as about 300 million for QVAR solution MDIs and as low as 670,000 for Beclovent MDIs. The number of particles in MDI aerosols was shown to be highly dependent on the mass median aerodynamic diameter (MMAD) and geometric standard deviation, and to a lesser extent the total mass of the aerosol. It was demonstrated that when the number of particles are calculated assuming that the aerosol is monodisperse and using the MMAD as the particle size, the number of particles are significantly underestimated. The number of droplets atomized from HFA-134a MDIs was estimated to range from about 220 million to about 1.1 billion droplets per actuation. For solution MDIs, each of the atomized droplets contains drug and thus the number of drug particles is the same as the number of atomized droplets. However, for suspension MDI formulations many of the droplets do not contain any micronized drug particles and the number of drug particles is much lower than the number of atomized droplets.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18446470      PMCID: PMC2976893          DOI: 10.1208/s12249-007-9006-8

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  5 in total

1.  Size distribution measurements of metered dose inhalers using Andersen Mark II cascade impactors.

Authors:  S W Stein
Journal:  Int J Pharm       Date:  1999-09-10       Impact factor: 5.875

Review 2.  Why particle size should affect clinical response to inhaled therapy.

Authors:  P H Howarth
Journal:  J Aerosol Med       Date:  2001

3.  Theoretical relationship of lung deposition to the fine particle fraction of inhalation aerosols.

Authors:  A J Hickey; T B Martonen; Y Yang
Journal:  Pharm Acta Helv       Date:  1996-08

4.  Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 Aerodynamic Particle Sizer aerosol spectrometer.

Authors:  Jolyon P Mitchell; Mark W Nagel; Kimberly J Wiersema; Cathy C Doyle
Journal:  AAPS PharmSciTech       Date:  2003-10-22       Impact factor: 3.246

5.  A theoretical and experimental analysis of formulation and device parameters affecting solution MDI size distributions.

Authors:  Stephen W Stein; Paul B Myrdal
Journal:  J Pharm Sci       Date:  2004-08       Impact factor: 3.534

  5 in total
  3 in total

1.  Effect of Inhalation Flow Rate on Mass-Based Plume Geometry of Commercially Available Suspension pMDIs.

Authors:  Daniel F Moraga-Espinoza; Eli Eshaghian; Albert Shaver; Hugh D C Smyth
Journal:  AAPS J       Date:  2018-07-12       Impact factor: 4.009

2.  Factors influencing aerodynamic particle size distribution of suspension pressurized metered dose inhalers.

Authors:  Poonam Sheth; Stephen W Stein; Paul B Myrdal
Journal:  AAPS PharmSciTech       Date:  2014-10-02       Impact factor: 3.246

3.  Tuning aerosol particle size distribution of metered dose inhalers using cosolvents and surfactants.

Authors:  Imran Y Saleem; Hugh D C Smyth
Journal:  Biomed Res Int       Date:  2013-07-24       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.